First 10-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients
Thursday, April 30, 2009 - 09:49
in Health & Medicine
SEATTLE, WA - April 30, 2009 - Biogen Idec (NASDAQ: BIIB) today announced data results from the CHAMPIONS (Controlled High-Risk AVONEX(R) (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study).
